TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9663183
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered over a 24‐hour period every 2 to 3 weeks for 6 months.
Study: 9663183
Drug: Intravenous dobutamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dobutamine and placebo groups.
Study: 2956297
Drug: Elase solution
DrugBank: Fibrinolysin (DB05254)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elase solution
Study: 2956297
Drug: Saline (placebo)
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline (placebo) solution
Study: 29709235
Drug: MDH2008 protocol
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDH2008 protocol (adapted to therapeutic response to 2 cycles of chemotherapy)
Study: 23614743
Drug: Hypericum perforatum
Normalized name: Hypericum perforatum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypericum perforatum extract rich in hyperforin cream
Study: 16343236
Drug: Paclitaxel 175
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 175 mg/m², Carboplatin AUC 5, Gemcitabine 800 mg/m² on day 1 and 800 mg/m² on day 8, every 3 weeks for six courses (TCG regimen)
Study: 16343236
Drug: Standard TC
Normalized name: TC-6987
DrugBank: TC-6987 (DB14854)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard TC regimen (175 mg/m² 3 h/AUC 5 day 1 q 21 x 6)
Study: 7864415
Drug: Oral meperidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral meperidine (3 mg/kg) with pentobarbital (4 mg/kg)
Study: 7864415
Drug: Nasal ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal ketamine (5 mg/kg) with midazolam (0.2 mg/kg)
Study: 7864415
Drug: Rectal methohexital
Normalized name: Methohexital
DrugBank: Methohexital (DB00474)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rectal methohexital (30 mg/kg)
Study: 1950542
Drug: Higher doses
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher doses of allergen
Study: 1950542
Drug: Allergen (any
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allergen (any dose)
Study: 7020738
Drug: Radiophosphorus therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiophosphorus therapy
Study: 25921348
Drug: Cardiac resynchronization
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac resynchronization therapy (CRT) in patients with baseline PR interval ≥180 ms
Study: 25921348
Drug: Cardiac resynchronization
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac resynchronization therapy (CRT) in patients with baseline PR interval <180 ms
Study: 21548660
Drug: Etamicastat 200
Normalized name: Etamicastat
DrugBank: Etamicastat (DB15288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etamicastat 200 mg after fasting
Study: 21548660
Drug: Etamicastat 200
Normalized name: Etamicastat
DrugBank: Etamicastat (DB15288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etamicastat 200 mg after a high-fat meal
Study: 16478838
Drug: Budesonide (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (160 microg, two inhalations qd) plus terbutaline (0.4 mg) as needed
Study: 12790763
Drug: Dosulepine (25‐125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosulepine (25‐125 mg daily for 4‐8 weeks)
Study: 18687165
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (valsartan 160 mg + hydrochlorothiazide 12.5 mg)
Study: 1762385
Drug: Potassium chloride
Normalized name: Potassium Chloride
DrugBank: Potassium chloride (DB00761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Potassium chloride (KCl) 80 mmol K+ daily
Study: 1762385
Drug: Potassium citrate/bicarbonate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium citrate/bicarbonate (K-cit/bic) 80 mmol K+ daily
Study: 6573315
Drug: Cefotetan 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotetan 0.25 g
Study: 6573315
Drug: Cefotetan 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotetan 2.0 g
Study: 6573315
Drug: Cefotetan (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotetan (all doses)
Study: 30893392
Drug: Halobetasol propionate
Normalized name: Halobetasol Propionate
DrugBank: Ulobetasol (DB00596)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Halobetasol propionate lotion 0.01%
Study: 26487393
Drug: Training as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Training as usual supplemented by change agent interactions after the training
Study: 25091662
Drug: Oral monovalent
Normalized name: rotavirus, monovalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral monovalent rotavirus vaccine
Study: 19659407
Drug: Telephone-based osteoporosis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone-based osteoporosis clinic with monthly telephone follow-up
Study: 15066665
Drug: Posaconazole (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posaconazole (2 x 100 mg once daily for 10 days)
Study: 10448637
Drug: MDF treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDF treatment (5 times over 21 weeks)
Study: 10448637
Drug: MDF treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDF treatment
Study: 2241185
Drug: YNK01 single
Approvals — FDA: no, EMA: no, PMDA: no
Description: YNK01 single administration (800 mg/body/day)
Study: 2241185
Drug: YNK01 5-day
Approvals — FDA: no, EMA: no, PMDA: no
Description: YNK01 5-day administration (300 mg/body/day)
Study: 2241185
Drug: YNK01 5-day
Approvals — FDA: no, EMA: no, PMDA: no
Description: YNK01 5-day administration (500 mg/body/day)
Study: 2241185
Drug: 5-day administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-day administration of YNK01
Study: 27739091
Drug: Low-dose alcohol
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose alcohol (0.04 g/dl)
Study: 27739091
Drug: Moderate-dose alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moderate-dose alcohol (0.065 g/dl)
Study: 22938728
Drug: Conventional CVCs
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional CVCs (CC)
Study: 3047581
Drug: Dexamethasone (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (0.15 mg per kilogram of body weight every six hours for four days)
Study: 2025471
Drug: flumazenil 0.1-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: flumazenil 0.1-2 mg
Study: 2025471
Drug: flumazenil 0.1-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: flumazenil 0.1-2 mg (for diazepam sedation)
Study: 2025471
Drug: flumazenil 0.1-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: flumazenil 0.1-2 mg (for midazolam sedation)
Study: 2025471
Drug: flumazenil 0.1-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: flumazenil 0.1-2 mg and placebo
Study: 31791415
Drug: Intervention package
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intervention package (condom promotion, HIV and syphilis testing, reimbursement for syphilis treatment costs, and free anti-retroviral therapy)
Study: 28720121
Drug: Daily SMS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily SMS reminders of antihypertensive medication intake provided by pharmacists in addition to standard pharmaceutical care
Study: 26096637
Drug: Perampanel (4,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perampanel (4, 8, and 12 mg)
Study: 19221011
Drug: 50 g
Normalized name: glucose 50 g/296 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g sucrose in water (500 ml)
Study: 19221011
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg sucralose in 500 ml normal saline (0.4 mM)
Study: 19221011
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg sucralose in 500 ml normal saline (4 mM)
Study: 19221011
Drug: 500 ml
Normalized name: TPN Bag 500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 ml normal saline
Study: 11286849
Drug: Accelerator A
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerator A (used for treatment)
Study: 11286849
Drug: Accelerator B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerator B (used for treatment)
Study: 2729180
Drug: High-dose metoclopramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose metoclopramide (2 mg/kg X 4)
Study: 2729180
Drug: Metoclopramide plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide plus high-dose methylprednisolone (250 mg X 2)
Study: 9470834
Drug: CVI 5‐FU
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVI 5‐FU at a dose of 750 mg/m2/day, 7 d every 21 d (n = 77)
Study: 9470834
Drug: Bolus 5‐FU
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus 5‐FU 500 mg/m2/d x 5 d every 28 d (n = 78)
Study: 3370065
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg torasemide once daily
Study: 3370065
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg torasemide once daily
Study: 3370065
Drug: Torasemide treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Torasemide treatment
Study: 19768454
Drug: Bupivicaine 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivicaine 0.5% (20 ml)
Study: 19768454
Drug: Bupivicaine 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivicaine 0.5% (20 ml) with 10 mg morphine
Study: 18333861
Drug: Maraviroc (3-1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maraviroc (3-1200 mg)
Study: 16003291
Drug: Verapamil (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (240 mg daily for 6 days)
Study: 12479993
Drug: Therapist-administered group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapist-administered group training (TG)
Study: 10065784
Drug: Standard infertility
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard infertility treatment algorithm (group 2)
Study: 2257872
Drug: Rythmodan (conventionally
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rythmodan (conventionally formulated disopyramide) 150 mg
Study: 2257872
Drug: Rythmodan 250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rythmodan 250 mg
Study: 2257872
Drug: Rythmodan Retard
Normalized name: diclofenac sodium Extended Release Oral Tablet [Lofensaid Retard]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rythmodan Retard (controlled‐release disopyramide) 250 mg
Study: 30962231
Drug: Provision of
Normalized name: Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Provision of health behaviour change resources alone (1-year commercial weight loss programme membership, self-monitoring tools, health education, and monthly check-ins)
Study: 27100913
Drug: Dexmedetomidine sedation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine sedation (IV bolus of 1 mcg/kg over 10 min followed by maintenance infusion of 0.5 mcg/kg/h)
Study: 22765352
Drug: Action observation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Action observation treatment (observing video clips showing daily age-appropriate actions and imitating them)
Study: 19015065
Drug: Various therapeutic
Normalized name: Various therapeutic radiopharmaceuticals
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various therapeutic approaches including surgery, radiotherapy, and chemotherapy
Study: 15644821
Drug: 0.37 mg/kg/week
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.37 mg/kg/week
Study: 15644821
Drug: 0.24 mg/kg/week
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.24 mg/kg/week
Study: 15644821
Drug: 0.24‐‐>0.37 mg/kg/week
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.24‐‐>0.37 mg/kg/week
Study: 8570130
Drug: RT plus
Normalized name: Recort Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: RT plus MLT (20 mg/daily orally)
Study: 1279821
Drug: Somatostatin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin (250 micrograms per hour continuous intravenous infusion for three days)
Study: 4022350
Drug: Azathioprine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azathioprine (2 mg/kg) with prednisone
Study: 31618129
Drug: Bevacizumab plus
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab plus chemotherapy (BC)
Study: 29688582
Drug: Oral esaxerenone
Normalized name: Esaxerenone
DrugBank: Esaxerenone (DB15207)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Oral esaxerenone (5-200 mg single-dose; 10-100 mg multiple-dose over 10 days)
Study: 29688582
Drug: Oral esaxerenone
Normalized name: Esaxerenone
DrugBank: Esaxerenone (DB15207)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Oral esaxerenone (single-dose)
Study: 29688582
Drug: Oral esaxerenone
Normalized name: Esaxerenone
DrugBank: Esaxerenone (DB15207)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Oral esaxerenone (multiple-dose)
Study: 24817035
Drug: JNJ 39758979
Normalized name: JNJ-39758979
DrugBank: JNJ-39758979 (DB18899)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ 39758979 (600 mg)
Study: 22448783
Drug: Lu AA21004
Normalized name: Lu-DOTA-TATE
DrugBank: Lutetium Lu 177 dotatate (DB13985)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lu AA21004 (75 mg single dosing, 60 mg multiple dosing)
Study: 17689896
Drug: Chinese herbal
Normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese herbal medicines (CHM)
Study: 15059637
Drug: Antioxidants (AO)
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidants (AO) - 1000 mg vitamin C and 400 IU RRR-alpha-tocopheryl acetate
Study: 11584934
Drug: Combination regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination regimen (pentamidine 2 mg/kg IM on alternate days + allopurinol 15 mg/kg in three divided doses for 30 days)
Study: 11584934
Drug: Single regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single regimen (pentamidine 4 mg/kg IM on alternate days for 15 injections in 30 days)
Study: 6813444
Drug: D,L-carnitine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: D,L-carnitine (50 mg/kg/day) for four weeks
Study: 30585986
Drug: Bediol (13.4‐mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bediol (13.4‐mg THC, 17.8‐mg CBD)
Study: 25847054
Drug: ToM treatment
Normalized name: BENZALKONIUM CHLORIDE 1.3 mg in 1 mL TOPICAL SOLUTION [7 SELECT Cold Sore Symptom Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: ToM treatment
Study: 24599650
Drug: BMAC combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMAC combined with PRP injection
Study: 22379071
Drug: Inhaled tobramycin/oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled tobramycin/oral ciprofloxacin (arm B)
Study: 22379071
Drug: Inhaled colistin/oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled colistin/oral ciprofloxacin (arm A)
Study: 21180141
Drug: CoQ10 100
Normalized name: Walgreens CoQ10 100mg Softgel
Approvals — FDA: no, EMA: no, PMDA: no
Description: CoQ10 100 mg/d (Q group)
Study: 15502602
Drug: d-threo-methylphenidate hydrochloride
Normalized name: d-threo-methylphenidate
DrugBank: Dexmethylphenidate (DB06701)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: d-threo-methylphenidate hydrochloride (d-MPH) at doses of 2.5, 5, or 10 mg
Study: 15502602
Drug: d,l-threo-methylphenidate hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: d,l-threo-methylphenidate hydrochloride (dl-MPH) at doses of 5, 10, or 20 mg
Study: 9523054
Drug: Chronic oral
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic oral magnesium supplementation
Study: 9523054
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium sulfate infusions
Study: 1865975
Drug: MSD vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MSD vaccine
Study: 7469623
Drug: Aspirin (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (single dose ranging from 325 to 2,925 mg)
Study: 7469623
Drug: Acetaminophen (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (single dose ranging from 975 to 1,950 mg)
Study: 23553888
Drug: Primary PCI
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary PCI for STEMI (no specific dosage or duration mentioned)
Study: 19925199
Drug: Cue-induced proactive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cue-induced proactive preparation and maintenance processes
Study: 15470338
Drug: ACE inhibitor
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitor group (N = 19)
Study: 15470338
Drug: No ACE
Normalized name: Amino Acetic Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: No ACE inhibitor group (N = 12)
Study: 15470338
Drug: Smokers (ACE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smokers (ACE inhibitor group)
Study: 15470338
Drug: Nonsmokers (ACE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsmokers (ACE inhibitor group)
Study: 9877003
Drug: Tolrest (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolrest (50 mg)
Study: 7961548
Drug: Antidepressant selection
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant selection based on medical illness and therapeutic regimen
Study: 31876704
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate cream (MMF) applied once a day from the date of first radiotherapy until 2 weeks after end of radiotherapy or until ARD lesions developed.
Study: 31876704
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate cream (MMF) applied once a day.
Study: 31876704
Drug: Control side
Normalized name: cured fat, pork side bacon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control side (no medication applied).
Study: 25119563
Drug: Lichtenstein (L)
Normalized name: L-377202
DrugBank: L-377202 (DB19022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lichtenstein (L) technique
Study: 22740100
Drug: Worksite lifestyle
Normalized name: Workvie
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Worksite lifestyle intervention (6-month duration, including two weekly guided group sessions: one yoga and one workout, one weekly session of aerobic exercising, and three individual coach visits)
Study: 22020346
Drug: Ketamine (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (0.8 mg/kg per hour during 80 minutes with approximate target plasma levels of 200 ng/mL)
Study: 14632207
Drug: Sunscreen with
Normalized name: ZINC OXIDE 0.1995 g in 1 g TOPICAL CREAM [SilkShield All Mineral Sunscreen with TriHex Technology]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunscreen with high ultraviolet A absorption (ultraviolet A protection factor of 10, SPF 15)
Study: 14632207
Drug: Sunscreen with
Normalized name: ZINC OXIDE 0.1995 g in 1 g TOPICAL CREAM [SilkShield All Mineral Sunscreen with TriHex Technology]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunscreen with low ultraviolet A absorption (ultraviolet A protection factor of 2, SPF 15)
Study: 10712996
Drug: Generic albuterol
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic albuterol metered-dose inhaler (MDI) - 1 actuation (90 microg)
Study: 10712996
Drug: Generic albuterol
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic albuterol metered-dose inhaler (MDI) - 4 actuations (360 microg)
Study: 10712996
Drug: Ventolin metered-dose
Normalized name: albuterol Metered Dose Inhaler [Ventolin]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ventolin metered-dose inhaler (MDI)
Study: 1390328
Drug: Verapamil (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (5 mg intravenously and 80 mg tid orally)
Study: 3903528
Drug: 160 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160 mg/day i.v. for 3 days, then oral MP (0.8 mg/kg/day) tapered by 4 mg/week to 16 mg/day
Study: 3903528
Drug: 80 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg/day i.v. for 3 days, then oral MP (0.4 mg/kg/day) tapered by 2 mg/week to 16 mg/day
Study: 31820600
Drug: Acupuncture combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture combined with tropisetron hydrochloride (5 mg, slow intravenous injection, once a day for 3 days) in No.1 observation group.
Study: 31820600
Drug: Acupuncture after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture after chemotherapy combined with tropisetron hydrochloride (5 mg, slow intravenous injection, once a day for 3 days) in No.2 observation group.
Study: 31820600
Drug: Tropisetron hydrochloride
Normalized name: tropisetron hydrochloride
DrugBank: Tropisetron (DB11699)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tropisetron hydrochloride (5 mg, slow intravenous injection, once a day for 3 days) in control group.
Study: 30322824
Drug: Minocycline (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minocycline (200 mg per day for 2 weeks, then 300 mg per day for the remainder of the 12‐month study period)
Study: 27086089
Drug: Simvastatin 40
Normalized name: simvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 40 mg once daily for 3 to 7 days preoperatively until 14 days postoperatively
Study: 17604332
Drug: Ketorolac Bier
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac Bier block (6 mg of ketorolac tromethamine in saline)
Study: 7208541
Drug: 350 mg
Normalized name: hemin 350 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 350 mg pivampicillin 3-times a day
Study: 28784120
Drug: Commonly prescribed
Normalized name: Common carp
DrugBank: Common carp (DB10614)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commonly prescribed antihypertensive medication
Study: 19450037
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy plus hypnosis (CBTH) in addition to standard medical care (SMC) (n = 22)
Study: 15000763
Drug: Oralin spray
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oralin spray (100 U)
Study: 15000763
Drug: OHAs (metformin
Approvals — FDA: no, EMA: no, PMDA: no
Description: OHAs (metformin + glyburide)